Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Semin Arthritis Rheum. 2019 Nov 15;50(3):546–552. doi: 10.1016/j.semarthrit.2019.11.004

Table 3:

Treatment characteristics of 77 cardiac sarcoidosis patients

Treatment Full Cohort (n =77) Definite CS (n =ll) Probable CS (n =31) Possible CS (n = 35)
Glucocorticoids
 Prednisone 69 (90) 5 31 33
Steroid-sparing agents 57 (74) 3 27 27
 Methotrexate 55 (71) 3 27 25
 Leflunomide 2 (3) 0 2 0
 Azathioprine 8 (10) 0 6 2
 Mycophenolate mofetil 4 (5) 0 3 1
 Hydroxycloroquine 5 (7) 0 5 0
TNF-α inhibitors 20 (26) 3 10 7
 Infliximab 10 (13) 1 5 4
 Adalimumab 10 (13) 2 6 2
 Golimumab 1 (1) 0 0 1
*

Data are number (%). CS = cardiac sarcoidosis; TNF-α = tumor necrosis factor alpha.